Drug:
Reaction: ECZEMA
20250101 - 20251231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 25491682 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 2 | 25491899 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, PROPRANOLOL HYDROCHLORIDE, MAGNESIUM, ERGOCALCIFEROL, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, EPINEPHRINE, ADRENALINUM, |
||||
| 3 | 25491902 |
US |
23 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 4 | 25491915 |
US |
33 | 1 |
Dry skin, Eczema, Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 5 | 25491919 |
US |
25 | 1 |
Eczema, Rash, Eye pruritus, |
||||
DUPILUMAB, |
||||
| 6 | 25495040 |
FR |
78 | 2 |
Pruritus, Diarrhoea, Eczema, Hypothyroidism, Neuropathy peripheral, Hypoaesthesia, Lacrimation increased, Oedema peripheral, Periorbital oedema, Paraesthesia, |
||||
METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, AMLODIPINE, RAMIPRIL, FUROSEMIDE, DESLORATADINE, MOMETASONE FUROATE, MORPHINE, |
||||
| 7 | 25495580 |
US |
36 | 1 |
Eczema, Skin irritation, Rash, |
||||
DUPILUMAB, |
||||
| 8 | 25495584 |
US |
29 | 2 |
Food allergy, Urticaria, Eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 9 | 25495608 |
US |
17 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 10 | 25495658 |
US |
9 | 1 |
Eczema, Pruritus, |
||||
DUPILUMAB, |
||||
| 11 | 25495670 |
US |
60 | 1 |
COVID-19, Eczema, Pruritus, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE, LEVOCETIRIZINE DIHYDROCHLORIDE, MONTELUKAST SODIUM, MONTELUKAST, MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 12 | 25495707 |
US |
28 | 2 |
Eczema, Dry skin, Skin hyperpigmentation, Pruritus, Skin fissures, Maternal exposure during pregnancy, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 13 | 25495738 |
US |
65 | 2 |
Eczema, Intentional product misuse, Dental operation, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 14 | 25495771 |
US |
45 | 1 |
Eczema, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 15 | 25495804 |
US |
70 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 16 | 25495806 |
US |
4 | 2 |
Eczema, Contraindicated product administered, |
||||
DUPILUMAB, |
||||
| 17 | 25495880 |
US |
5 | 2 |
Eczema, Rash, |
||||
DUPILUMAB, |
||||
| 18 | 25495885 |
US |
8 | 2 |
Eczema, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 19 | 25495921 |
US |
5 | 2 |
Rash erythematous, Pain, Urticaria, Eczema, |
||||
DUPILUMAB, |
||||
| 20 | 25496058 |
US |
1 | |
Rash pruritic, Eczema, Skin swelling, |
||||
DUPILUMAB, |
||||
| 21 | 25496350 |
US |
24 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 22 | 25490938 |
US |
57 | 1 |
Upper respiratory tract infection, Cough, Eczema, |
||||
DUPILUMAB, |
||||
| 23 | 25490976 |
US |
2 | |
Inappropriate schedule of product administration, Eczema, Rash, |
||||
DUPILUMAB, |
||||
| 24 | 25491040 |
US |
74 | 2 |
Eczema, Acne, Pruritus, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 25 | 25491067 |
US |
19 | 2 |
Headache, Eczema, |
||||
DUPILUMAB, |
||||
| 26 | 25491199 |
US |
14 | 2 |
Fatigue, Eczema, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 27 | 25491250 |
US |
61 | 2 |
Mood altered, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 28 | 25491262 |
US |
28 | 2 |
Injection site pain, Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 29 | 25491292 |
US |
2 | 1 |
Eczema, Pruritus, Dry skin, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 30 | 25491303 |
US |
32 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 31 | 25491380 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 32 | 25491394 |
US |
57 | 2 |
Eczema, Ocular hyperaemia, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 33 | 25491413 |
US |
65 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 34 | 25491623 |
US |
7 | 2 |
Headache, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 35 | 25491628 |
US |
77 | 2 |
Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 36 | 25489991 |
US |
48 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 37 | 25490122 |
US |
3 | 1 |
Eczema, Pruritus, Erythema, |
||||
DUPILUMAB, |
||||
| 38 | 25490123 |
US |
19 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 39 | 25490331 |
US |
1 | |
Eczema, Dermatitis contact, |
||||
EVOLOCUMAB, |
||||
| 40 | 25490338 |
US |
50 | 2 |
Eczema, Dry skin, Skin exfoliation, Pruritus, Dry eye, |
||||
DUPILUMAB, |
||||
| 41 | 25490360 |
US |
17 | 2 |
Eye pruritus, Ocular hyperaemia, Lacrimation increased, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 42 | 25490400 |
US |
66 | 2 |
Pruritus, Eczema, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 43 | 25490810 |
US |
13 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 44 | 25490901 |
US |
54 | 2 |
Eczema, Therapeutic response shortened, Dermatitis atopic, Hypersensitivity, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 45 | 25486440 |
US |
15 | 1 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 46 | 25487320 |
AE |
3 | 1 |
Subdural haemorrhage, Microcephaly, Developmental delay, Eczema, Partial seizures, Gingival bleeding, |
||||
EMICIZUMAB, |
||||
| 47 | 25489196 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 48 | 25489241 |
US |
80 | 2 |
Lichen planus, Arthropod bite, Eczema, |
||||
DUPILUMAB, |
||||
| 49 | 25489245 |
US |
1 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 50 | 25489328 |
US |
93 | 1 |
Eczema, Urticaria, Pruritus, |
||||
DUPILUMAB, |
||||
| 51 | 25489339 |
US |
25 | 1 |
Eczema, Pruritus, Sleep disorder due to a general medical condition, Surgery, |
||||
DUPILUMAB, |
||||
| 52 | 25489358 |
US |
16 | 2 |
Eczema, Scab, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 53 | 25489435 |
US |
48 | 2 |
Eczema, |
||||
DUPILUMAB, NALTREXONE, ESCITALOPRAM, GABAPENTIN, PROPRANOLOL HYDROCHLORIDE, MAGNESIUM, NALTREXONE, DICLOFENAC SODIUM, POLYETHYLENE GLYCOL 3350, HYDROXYZINE, MINOCYCLINE, MUPIROCIN, MUPIROCIN CALCIUM, |
||||
| 54 | 25489490 |
US |
3 | 2 |
Rash macular, Skin haemorrhage, Ocular hyperaemia, Eye pruritus, Eczema, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 55 | 25489493 |
US |
43 | 1 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 56 | 25489498 |
US |
21 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 57 | 25490438 |
US |
34 | 2 |
Eczema, Pruritus, Erythema, Dermatitis, |
||||
DUPILUMAB, RUXOLITINIB, |
||||
| 58 | 25490619 |
US |
54 | 2 |
Eczema, Erythema, Pruritus, |
||||
DUPILUMAB, |
||||
| 59 | 25483689 |
AR |
2 | |
Cellulitis, Rash macular, Pityriasis rosea, Epidermal necrosis, Abscess limb, Skin burning sensation, Pustule, Subcorneal pustular dermatosis, Pruritus, Hypersensitivity, Pyrexia, Skin exfoliation, Acanthosis, Eczema, Superficial inflammatory dermatosis, Parakeratosis, Seborrhoeic dermatitis, Hypochromic anaemia, Infection, Wound, Gastrointestinal disorder, Condition aggravated, C-reactive protein increased, Hypochromic anaemia, Haemoglobin decreased, Oedema, Off label use, |
||||
CANAKINUMAB, CANAKINUMAB, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 60 | 25484119 |
US |
2 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 61 | 25484126 |
US |
45 | 2 |
Skin lesion, Erythema, Pruritus, Skin swelling, Dermatitis acneiform, Oral herpes, Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 62 | 25484130 |
US |
2 | |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 63 | 25484163 |
US |
54 | 1 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 64 | 25484209 |
US |
24 | 1 |
Discomfort, Eczema, Intentional dose omission, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 65 | 25484216 |
US |
55 | 2 |
Eczema, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 66 | 25484298 |
US |
57 | 2 |
Eczema, Pruritus, |
||||
DUPILUMAB, |
||||
| 67 | 25484368 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 68 | 25484391 |
US |
1 | |
Injection site reaction, Eczema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 69 | 25484434 |
US |
22 | 2 |
Eczema, Dry skin, Pruritus, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 70 | 25484772 |
US |
2 | 1 |
Pruritus, Urticaria, Rash, Eczema, |
||||
DUPILUMAB, |
||||
| 71 | 25485237 |
GB |
2 | |
Rash, Urticaria, Eczema, |
||||
TIRZEPATIDE, TIRZEPATIDE, CANDESARTAN, |
||||
| 72 | 25485300 |
US |
65 | 2 |
Eczema, Therapeutic product effect decreased, |
||||
DUPILUMAB, |
||||
| 73 | 25485400 |
US |
74 | 1 |
Eczema, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 74 | 25485664 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 75 | 25485690 |
US |
||
Eczema, Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 76 | 25485694 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 77 | 25485858 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 78 | 25485874 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 79 | 25485907 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 80 | 25485916 |
US |
||
Eczema, Pain in extremity, Chills, Malaise, Skin exfoliation, Erythema, Skin discolouration, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 81 | 25485938 |
US |
||
Eczema, Pain, Inappropriate schedule of product administration, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 82 | 25485953 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 83 | 25485957 |
US |
||
Pruritus, Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 84 | 25485994 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 85 | 25485998 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 86 | 25486000 |
US |
||
Rash, Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 87 | 25486005 |
US |
||
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 88 | 25486030 |
US |
||
Eczema, Skin burning sensation, Rash, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 89 | 25475943 |
US |
72 | 1 |
Sensitive skin, Eczema, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 90 | 25475982 |
US |
2 | |
Injection site pain, Eczema, Dry skin, |
||||
DUPILUMAB, |
||||
| 91 | 25476015 |
US |
27 | 2 |
Eczema, Rash macular, Rash, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 92 | 25476076 |
US |
54 | 2 |
Eczema, Rash, Pruritus, |
||||
DUPILUMAB, |
||||
| 93 | 25476127 |
US |
31 | 2 |
Injection site vesicles, Injection site pain, Eczema, Needle issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 94 | 25476155 |
US |
10 | 1 |
Eczema, Pruritus, Dry skin, Skin exfoliation, Erythema, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 95 | 25476486 |
US |
2 | |
Dermatitis contact, Eczema, |
||||
UPADACITINIB, |
||||
| 96 | 25476580 |
US |
1 | |
Colitis, Tooth loss, Gingival swelling, Eczema, Rash, |
||||
DUPILUMAB, ADALIMUMAB, CARVEDILOL, PANTOPRAZOLE SODIUM, PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, GABAPENTIN, NALTREXONE HYDROCHLORIDE, ADALIMUMAB-ADAZ, |
||||
| 97 | 25478066 |
ES |
1 | |
Eczema, Dermatitis exfoliative generalised, |
||||
AVATROMBOPAG MALEATE, |
||||
| 98 | 25479482 |
US |
2 | |
Sinusitis, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 99 | 25479485 |
US |
36 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 100 | 25479526 |
US |
69 | 1 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-07-29